Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.

• 目的探讨急性髓性白血病在经过混合造血干细胞移植(mixed-HSCT)后,应用供体淋巴细胞输注(DLI)+白介素-2(IL-2)作为后续免疫生物治疗措施的意义。